Clinical trials: Insulin-Like Growth Factor I
Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer
QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
This is a multi-center, 2-part study of AMG 655, AMG 479 or AMG 655-placebo plus gemcitabine as first-line treatment of subjects with metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer
- Trial name
- NCT00630552
- Testing
- AMG 479, AMG 655
- Where
- 44 sites in United States
- Volunteers
- 138 people
- Sponsor
- NantCell, Inc.
Rectal Neoplasms
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (IV) dalotuzumab (MK-0646) + irinotecan therapy relative to…
- Trial name
- NCT01609231
- Testing
- Dalotuzumab, Irinotecan, Cetuximab
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Failure, Chronic, Growth Hormone Deficiency
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
Treatment with growth hormone (GH; a hormone made by the body that stimulates growth) has been shown to be helpful in treating children with chronic kidney disease who fail to grow.
- Trial name
- NCT00212758
- Testing
- Nutropin AQ
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oregon Health and Science University
Advanced Squamous Non-Small Cell Lung Cancer
QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of…
- Trial name
- NCT00807612
- Testing
- AMG 479, Carboplatin, Paclitaxel
- Where
- 25 sites in United States
- Volunteers
- 15 people
- Sponsor
- NantCell, Inc.
Acromegaly
Effects of Sandostatin LAR® in Acromegaly
This study aims primarily to determine the effect Insulin-like Growth Factor 1 (IGF-1) normalization into current IGF-I normal ranges with Sandostatin LAR® therapy on biochemical metabolic, cardiovascular and body composition…
- Trial name
- NCT01424241
- Testing
- Sandostatin LAR
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Columbia University
Chronic Kidney Disease, End Stage Renal Disease
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients
The objective of this study is to determine MK-0677 increases IGF-1 in patients with end stage renal disease (ESRD) on hemodialysis.
- Trial name
- NCT00395291
- Testing
- MK-0677
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Virginia
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acromegaly
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma.
- Trial name
- NCT00171730
- Testing
- Pasireotide
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Insulin-like Growth Factor-1 Deficiency
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
IGF-1 (insulin-like growth factor-1) is a hormone that is normally produced in the body in response to another hormone called growth hormone. Growth Hormone is produced by a small gland at the base of the brain (the pituitary).
- Trial name
- NCT00572156
- Testing
- NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Ipsen
Thyroid Eye Disease
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- STRIVE (NCT06384547)
- Testing
- Veligrotug
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 231 people
- Sponsor
- Viridian Therapeutics, Inc.
Acromegaly
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly.
- Trial name
- NCT01412424
- Testing
- Octreotide capsules
- Where
- 36 sites in United States, Germany and 11 more
- Volunteers
- 155 people
- Sponsor
- Chiasma, Inc.
Advanced Solid Tumors
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
The purpose of this study is to determine if IMC-A12 is safe for participants, and also to determine the best dose of IMC-A12 to give to participants.
- Trial name
- NCT00785538
- Testing
- IMC-A12
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.
- Trial name
- NCT00125190
- Testing
- rhIGF-1 (mecasermin) for a period of 86 weeks
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
This randomized phase II trial is studying mitotane and IMC-A12 to see how well they work compared with mitotane alone in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by…
- Conditions
- Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
- Trial name
- NCT00778817
- Testing
- IMC-A12, mitotane
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Acromegaly, Type 2 Diabetes Mellitus
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Growth hormone (GH) and Insulin-like growth factor-I (IGF-I) secretion are altered in acromegaly and type 2 Diabetes Mellitis (DM).
- Trial name
- NCT00915954
- Testing
- Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Myotonic Dystrophy Type 1
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance, ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and strength, pain, gastrointestinal functioning, and…
- Trial name
- NCT00577577
- Testing
- rhIGF-I/rhIGFBP-3
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Insmed Incorporated
HIV, Inflammation
Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause
The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with Human Immunodeficiency Virus (HIV).
- Conditions
- HIV, Inflammation, Obesity, Aging, Biological
- Trial name
- NCT02404792
- Testing
- High-intensity cardiovascular and resistance exercise, Moderate-intensity cardiovascular and resistance exercise
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Myotonic Dystrophy
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 (SomatoKine-INSMED) as a treatment for muscle wasting and weakness in…
- Trial name
- NCT00233519
- Testing
- SomatoKine/IPLEX
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID)
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
This study will evaluate the safety and effectiveness of insulin-like growth factor-1 (IGF-1) to treat patients with X-linked severe combined immunodeficiency (XSCID).
- Conditions
- Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
- Trial name
- NCT00490100
- Testing
- Increlex
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Duchenne Muscular Dystrophy
Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy
The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).
- Trial name
- NCT01207908
- Testing
- IGF-1
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati